Cancer Treatment-Related Cardiotoxicity: Understanding the Current State of Knowledge and Developing Future Research Priorities
March 20 & 21, 2013
6001 Executive Boulevard
Rockville, MD 20852
Overview
The goals of anti-cancer therapies are to prevent recurrence, prolong life, and provide cure. Partly due to improvements in treatment, the population of cancer survivors is large and growing. However, cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in survivors of pediatric and adolescent cancers, after recurrence and second or subsequent malignancies. It is one of the most common post-treatment issues among five- to ten-year survivors of adult cancer. In addition, cancer patients may receive suboptimal therapy due to concern about potential cardiotoxicity, resulting in increased disease progression and mortality. The scientific knowledge gaps on cancer treatment-related cardiotoxicity are numerous, spanning basic and clinical science, and influence the advancement of science in this area. A joint effort of multiple disciplines within cardiology and oncology is required, thus this meeting includes leadership from the National Heart, Lung, and Blood Institute's (NHLBI) Division of Cardiovascular Sciences (DCVS) along with the National Cancer Institute's Divisions of Cancer Control and Population Sciences (DCCPS) and Cancer Prevention (DCP).
Purpose
This meeting will bring together multiple disciplines within cardiology and oncology to identify research priorities aimed at improving the cardiac outcomes of cancer survivors. Research in cancer treatment-related cardiotoxicities is dependent on research in all other aspects of cardiotoxicity, as well as the development of new therapies, screening, and treatments that will impact the epidemiology and genomics of cardiotoxicity. The goal of this meeting is to identify research priorities in the area of cancer treatment-related cardiotoxicity that will inform program announcements, other funding initiatives, and opportunities, and review articles describing current gaps and priorities for this important research area.
Agenda
| Wednesday, March 20 | Topic |
|---|---|
| 8:00 a.m. - 8:30 a.m. | Registration |
|
Workshop Introductions and Overview Moderator: Joanna Brell, M.D., Division of Cancer Prevention (DCP), NCI |
|
| 8:30 a.m. - 8:55 a.m. |
Welcome and Introductions
Robert T. Croyle, Ph.D. Lori Minasian, M.D. Michael Lauer, M.D. |
| 8:55 a.m. - 9:10 a.m. |
Workshop Overview and Objectives
Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N. |
| 9:10 a.m. - 9:25 a.m. |
Cancer Treatment-Related Cardiotoxicity: How Big is the Problem?
Andrew Freedman, Ph.D. |
| 9:25 a.m. - 9:40 a.m. |
Basic Science of Cancer Treatment-Related Cardiotoxicity
Thomas Force, M.D. |
|
Session 1: The Biology and Mechanisms of Cancer Treatment-Related Cardiotoxicity Moderator: Bishow Adhikari, Ph.D., DCVS, NHLBI |
|
| 9:40 a.m. - 10:00 a.m. |
Mechanisms of Cancer Treatment-Related Cardiotoxicity: Similarities/Connections with Cardiovascular Disease
Speaker: Aarif Khakoo, M.D. |
| 10:00 a.m. - 10:15 a.m. |
Contemporary Agents In Cancer Treatment-Related Cardiotoxicity
Speaker: Edward Yeh, M.D. |
| 10:15 a.m. - 10:30 a.m. |
Combination Cancer Therapy: The Cardiac Impact of Adding New Agents to Old Regimens
Speaker: Bonnie Ky, M.D., M.S.C.E. |
| 10:30 a.m. - 10:45 a.m. | BREAK |
| 10:45 a.m. - 11:00 a.m. |
Implications of Making a New Compound with Cardiotoxicity Potential: When Is the Toxicity Too Much?
Speaker: Colin Dollery, F.R.C.P. |
| 11:00 a.m. - 11:30 a.m. | Q&A / Open Discussion |
| 11:30 a.m. - 12:00 p.m. | Session 1 Priority Setting |
| 12:00 p.m. - 1:00 p.m. | LUNCH |
|
Session 2: Preclinical Drug Development and Screening Moderator: Myrtle Davis Millin, D.V.M., Ph.D., Division of Cancer Treatment Diagnosis (DCTD), NCI |
|
| 1:00 p.m. - 1:15 p.m. |
Models for Drug Development and Screening
Speaker: Kyle Kolaja, Ph.D. |
| 1:15 p.m. - 1:30 p.m. |
What Animal Models Are Available to Inform Early Phase Therapeutics?
Speaker: Thomas Force, M.D. |
| 1:30 p.m. - 1:45 p.m. |
The Role of Systems Biology in Cardiotoxicity Research
Speaker: Darrell Abernethy, M.D., Ph.D. |
| 1:45 p.m. - 2:00 p.m. |
Drug Redesign: Animal Models
Speaker: TBD |
| 2:00 p.m. - 2:30 p.m. | Q&A / Open Discussion |
| 2:30 p.m. - 3:00 p.m. | Session 2 Priority Setting |
| 3:00 p.m. - 3:15 p.m. | BREAK |
|
Session 3: Early Phase Therapeutics Moderator: Scot Remick, M.D., West Virginia University Health Sciences Center |
|
| 3:15 p.m. - 3:30 p.m. |
Approach to Standardization of Safety/Screening Measurements and Toxicity Grading in Early Phase Clinical Trials
Speaker: Daniel Lenihan, M.D. |
| 3:30 p.m. - 3:45 p.m. |
Identifying/Assessing Chemical Biomarkers in Early Phase Clinical Trials
Speaker: Javid Moslehi, M.D. |
| 3:45 p.m. - 4:00 p.m. |
Bridging/Applying Mechanism of Cancer Treatment-Related Cardiotoxicity to Screening and Risk Prediction
Speaker: Marielle Scherrer-Crosbie, M.D., Ph.D. |
| 4:00 p.m. - 4:30 p.m. | Q&A / Open Discussion |
| 4:30 p.m. - 5:00 p.m. | Session 3 Priority Setting |
| 5:00 p.m. | MEETING AJOURNS |
| Thursday, March 21 | Topic |
|---|---|
| 8:00 a.m. - 8:30 a.m. | Registration |
| 8:30 a.m. - 8:45 a.m. |
Clinical Care of Cancer Treatment-Related Cardiotoxicity
Speaker: Kevin Oeffinger, M.D. |
|
Session 4: Cancer Treatment-Related Cardiotoxicity: Risk, Screening, & Detection Moderator: Ming Hui Chen, M.D., MMSc, Boston Children's Hospital, Brigham and Women's Hospital, Harvard Medical School |
|
| 8:45 a.m. - 9:00 a.m. |
Epidemiology of Hypertension and Heart Muscle Toxicity in Cancer Care
Speaker: Michael Maitland, M.D., Ph.D. |
| 9:00 a.m. - 9:15 a.m. |
Pre-Treatment Risk Assessment of Cardiotoxicity: Pharmacogenomics
Speaker: Smita Bhatia, M.D., M.P.H. |
| 9:15 a.m. - 9:30 a.m. |
Pre-Treatment Risk Assessment of Cardiotoxicity: Metabolomics
Speaker: Robert Gerszten, M.D. |
| 9:30 a.m. - 9:45 a.m. |
Clinical Biomarkers in Primary Heart Failure: Detecting Asymptomatic Toxicity
Speaker: G. Michael Felker, M.D., M.H.S. |
| 9:45 a.m. - 10:00 a.m. |
Clinical Biomarkers in Cancer Treatment-Related Cardiotoxicity: Detecting Asymptomatic Toxicity
Speaker: Jean-Bernard Durand, M.D. |
| 10:00 a.m. - 10:15 a.m. |
Clinical Imaging: Detecting Asymptomatic Toxicity
Speaker: Juan Carlos Plana, M.D. |
| 10:15 a.m. - 10:30 a.m. |
The Patient's Perspective
Speaker: Neeraj Arora, Ph.D. |
| 10:30 a.m. - 11:00 a.m. | Q&A / Open Discussion |
| 11:00 a.m. - 11:30 a.m. | Session 4 Priority Setting |
| 11:30 a.m. - 12:30 p.m. | LUNCH |
|
Session 5: Cancer Treatment-Related Cardiotoxicity: Prevention & Treatment Moderator: Alice Mascette, M.D., DCVS, NHLBI |
|
| 12:30 p.m. - 12:45 p.m. |
Pharmacologic Methods for Prevention and Treatment of Hypertension
Speaker: Philip Sager, M.D. |
| 12:45 p.m. - 1:00 p.m. |
Pharmacologic Methods for Prevention & Treatment of Heart Muscle Toxicity
Speaker: Roberta Gottlieb, M.D. |
| 1:00 p.m. - 1:15 p.m. |
Pharmacologic Methods for Prevention of Cardiotoxicity in Breast Cancer
Speaker: Maya Guglin, M.D., Ph.D. |
| 1:15 p.m. - 1:30 p.m. |
Cardiovascular Exercise and Biomarkers in Cancer Survivors
Speaker: Jennifer Klemp, Ph.D., M.P.H. |
| 1:30 p.m. - 1:45 p.m. |
Nutrition in the Prevention and Treatment of Cardiotoxicity-Related Cancer Treatment-Related Cardiotoxicity
Speaker: Wendy Demark-Wahnefried, Ph.D., R.D. |
| 1:45 p.m. - 2:15 p.m. | Q&A / Open Discussion |
| 2:15 p.m. - 2:45 p.m. | Session 5 Priority Setting |
| 2:45 p.m. - 3:00 p.m. | BREAK |
|
Session 6: Establishing Cohorts and Translating Findings Moderator: Richard Steingart, M.D., F.A.C.C., Memorial Sloan-Kettering Cancer Center |
|
| 3:00 p.m. - 3:15 p.m. |
Barriers in the Development of Cancer Treatment-Related Cardiotoxicity Guidelines
Speaker: JoAnn Lindenfeld, M.D. |
| 3:15 p.m. - 3:30 p.m. |
Pharmacologic Methods for Prevention & Treatment of Heart Muscle Toxicity
Speaker: Gregory Armstrong, M.D., M.S.C.E. |
| 3:30 p.m. - 3:45 p.m. |
Pharmacologic Methods for Prevention of Cardiotoxicity in Breast Cancer
Speaker: Scot Remick, M.D. |
| 3:45 p.m. - 4:00 p.m. | Q&A / Open Discussion |
| 4:00 p.m. - 4:15 p.m. | Session 6 Priority Setting |
| 4:15 p.m. - 5:00 p.m. | Review and Vote on Research Priorities |
| 5:00 p.m. | ADJOURN |
Online Viewing
A live stream of the workshop will be available at http://videocast.nih.gov
. Video of the event will be recorded and archived for later viewing.
Additional Resources
- Cancer Treatment-Related Cardiotoxicity Research Articles
This list provides links to a compilation of scientific publications that may be of interest to researchers studying cardiotoxicities related to cancer treatments.
Contacts
Workshop Planning Committee:
- Scot Remick - co-chair, West Virginia University
- Thomas Force - co-chair, Temple University
- Nonniekaye Shelburne - NCI, Division of Cancer Control and Population Sciences
- Andrew Freedman - NCI, Division of Cancer Control and Population Sciences
- Joanna Brell - NCI, Division of Cancer Prevention
- Alice Mascette - NHLBI, Division of Cardiovascular Sciences
- Bishow Adhikari - NHLBI, Division of Cardiovascular Sciences
- Myrtle Davis-Millin - NCI, Division of Cancer Treatment Diagnosis
For further information or questions, contact Nonniekaye F. Shelburne, C.R.N.P., M.S., A.O.C.N. Program Director, Clinical and Translational Epidemiology Branch.
